Petra Doerr, head of sector communication & networking as well as deputy executive director of Swissmedic, the Swiss surveillance authority for medicines and medical devices, discusses changes to the Swiss regulatory system and harmonizing the organization with its global counterparts.
Swissmedic has embarked upon a comprehensive overhaul of its regulations in response to changes to the Therapeutic Products Act that were finalized last year. This has included reviewing drug ordinances to simplify pathways to market. What progress has been made thus far?
"Essentially, what we are expecting is a facilitated market access route for OTC products and generics"
